<DOC>
	<DOCNO>NCT00867308</DOCNO>
	<brief_summary>This single center open label phase II study lenalidomide IPSS Int-1 increase blast hematologic need 5q31.1 deletion fail respond standard dose lenalidomide. , IPSS Int-1 increase blast hematologic need without 5q31.1 deletion , Int-2 high risk myelodysplastic syndrome ( MDS ) patient without 5q31.1 deletion , regardless whether receive lenalidomide previously . Patients receive two cycle 50 mg daily lenalidomide give day 1-28 42 day cycle . Within two cycle lenalidomide , patient give three week drug treatment recover . Patients fail respond two cycle treatment may receive two additional cycle stable . Patients develop clinical response may continue receive drug disease progression .</brief_summary>
	<brief_title>Trial High Dose Lenalidomide Patients With Myelodysplastic Syndrome ( MDS ) Acute Myeloid Leukemia ( AML ) With Trilineage Dysplasia ( AML-TLD )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Age great than18 year time signing informed consent form . Able adhere study visit schedule protocol requirement . MDS MDS/AML Patients must receive treatment disease , include hematopoietic growth factor , within three week begin trial ECOG performance status 0 , 1 , 2 study entry All study participant must register mandatory REMS® program , willing able comply requirement RevAssist® . Patients must clinical evidence CNS pulmonary leukostasis , disseminate intravascular coagulation , CNS leukemia . Subjects must agree use appropriate contraception . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . Pregnant breast feeding female . ( Lactating female must agree breast feed take lenalidomide ) . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . Use experimental drug therapy within 21 day baseline . Known hypersensitivity thalidomide . The development erythema nodosum characterize desquamate rash take thalidomide similar drug . Any prior use lenalidomide except MDS patient del 5q31.1 abnormalities.. Concurrent use anticancer agent treatment . Patients may receive prior AML induction chemotherapy stem cell transplant . However , patient secondary MDS receive stem cell transplant indication ( eg lymphoma , multiple myeloma ) eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>IPSS Int-2</keyword>
	<keyword>high risk myelodysplastic syndrome</keyword>
	<keyword>MDS )</keyword>
	<keyword>5q31.1 deletion</keyword>
</DOC>